

# **Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening Type, Technology, Indication, and Region - Analysis and Forecast, 2021-2031**

<https://marketpublishers.com/r/C5B46015AA29EN.html>

Date: December 2021

Pages: 213

Price: US\$ 5,250.00 (Single User License)

ID: C5B46015AA29EN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

Market Report Coverage - Carrier Screening

Market Segmentation

Type (Expanded Carrier Screening and Targeted Carrier Screening)

Product (In Vitro Diagnostics And Laboratory Developed Tests)

Carrier Screening Type (Prenatal Carrier Screening And Preconception Carrier Screening)

Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, And Other Technologies)

Indication (Fragile X Syndrome, Cystic Fibrosis, Spinal Muscular Atrophy, Down's Syndrome, Thalassemia, Tay-Sachs Disease, Huntington's Disease, Sickle Cell Anemia, Hemophilia, and Other Indications)

Regional Segmentation

North America: U.S., Canada

Europe: Germany, France, U.K, Italy, Spain, Netherlands, Denmark, Belgium, Switzerland and Rest-of-Europe

Asia-Pacific: China, Japan, India, South Korea, Australia, Singapore, Rest-of-Asia-Pacific

Latin America: Brazil, Mexico, Rest-of-Latin America

Rest-of-the-World

## Market Growth Drivers

Decreasing Cost of Sequencing

Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders

Increasing Maternal Age Leading to Pregnancy Complications

Rising Funding and Innovation in the carrier Screening Ecosystem

## Market Challenges

Regulatory Challenges in the Field of Carrier Screening

Lack of High Complexity Testing Centers

Existing Diagnostic Confidence on Conventional Screening Methods

## Market Opportunities

Massive Scope for Adoption of Carrier Screening in Developing Nations

## Key Companies Profiled

BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., Yourgene Health Plc

## Key Questions Answered in this Report:

How is carrier screening revolutionizing the field of reproductive health?

What are the major market drivers, challenges, and opportunities in the global carrier screening market?

What are the underlying structures resulting in the emerging trends within the global carrier screening market?

How is the COVID-19 pandemic impacting the global carrier screening ecosystem??

What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?

What are the key regulatory implications in developed and developing regions pertaining to the use of carrier screening?

What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?

How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:

- o Type (expanded carrier screening and targeted carrier screening)
- o Product (in vitro diagnostics and laboratory developed tests)
- o Carrier Screening Type (prenatal carrier screening and preconception carrier

screening)

- o Technology (next-generation sequencing, polymerase chain reaction, microarray, and other technologies)

- o Indication (fragile X syndrome, cystic fibrosis, spinal muscular atrophy, Down's Syndrome, thalassemia, Tay-Sachs Disease, Huntington's Disease, sickle cell anemia, hemophilia, and other indications)

- o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

What are the growth opportunities for the carrier screening companies in the region of their operation?

Who are the leading players with significant offerings in the global carrier screening market?

Which companies are anticipated to be highly disruptive in the future, and why?

## Market Overview

The growth of the carrier screening market is expected to be driven by the decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications. However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers. Carrier screening is a hereditary test that gives information about whether a person carries a gene for certain genetic disorders. It is performed before or during pregnancy times. Carrier screening allows a person to find out the chances of having a child with a genetic disorder. Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder. A person who is a carrier has only one gene for a disorder and usually does not have symptoms or have only mild symptoms. The current market for carrier screening is majorly dominated by manufacturers and service providers such as BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher

Scientific Inc., and Yourgene Health Plc.

The global carrier screening market is projected to reach \$4,479.0 million by 2031, growing from \$1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.

The carrier screening market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down's syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA). Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health.

### Competitive Landscape

The growth of this market can be majorly attributed to the presence of well-established guidelines regarding carrier screening, presence of established companies undertaking key business strategies, decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications, among others. Further, increasing focus on research pertaining to carrier screening such as targeted carrier screening in spinal muscle atrophy and emerging application of preconception carrier screening is also expected to support the growth of the carrier screening market during the forecast period, 2021-2031.

The growth of other technologies, such as next-generation sequencing and PCR can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

## Contents

### 1 MARKET

- 1.1 Product Definition
  - 1.1.1 Inclusion and Exclusion
- 1.2 Market Scope
  - 1.2.1 Scope of the Study
  - 1.2.2 Key Questions Answered in the Report
- 1.3 Research Methodology
  - 1.3.1 Global Carrier Screening Market: Research Methodology
  - 1.3.2 Data Sources
    - 1.3.2.1 Primary Data Sources
    - 1.3.2.2 Secondary Data Sources
  - 1.3.3 Market Estimation Model
  - 1.3.4 Criteria for Company Profiling
- 1.4 Market Overview
  - 1.4.1 Emerging Applications of Carrier Screening
  - 1.4.2 Appropriate Use Criteria
    - 1.4.2.1 Carrier Screening for Familial Disease
      - 1.4.2.1.1 Fragile X Syndrome (FXS)
    - 1.4.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
      - 1.4.2.2.1 Cystic Fibrosis
      - 1.4.2.2.2 Spinal Muscular Atrophy
      - 1.4.2.2.3 Hemoglobinopathy
      - 1.4.2.2.4 Ashkenazi Jewish Carrier Screening
    - 1.4.2.3 Other Ethnicities
  - 1.4.3 Market Footprint and Growth Potential
  - 1.4.4 Disruption in Global Carrier Screening Market Due to COVID-19
  - 1.4.5 Navigating Crisis Recovery and Looking to the Future

### 2 INDUSTRY ANALYSIS

- 2.1 Overview
- 2.2 Legal Requirements and Framework in the U.S.
  - 2.2.1 U.S. Food and Drug Administration (FDA)
  - 2.2.2 American College of Medical Genetics and Genomics (ACMG)
  - 2.2.3 American College of Obstetricians and Gynecologists
- 2.3 Legal Requirements and Framework in Europe

## 2.4 Legal Requirements and Framework in Asia-Pacific

### 2.4.1 China

### 2.4.2 Japan

## 2.5 Reimbursement Analysis

# 3 MARKET DYNAMICS

## 3.1 Overview

## 3.2 Impact Analysis

## 3.3 Market Drivers

### 3.3.1 Decreasing Cost of Sequencing

### 3.3.2 Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders

### 3.3.3 Increasing Maternal Age Leading to Pregnancy Complications

### 3.3.4 Rising Funding and Innovation in the Carrier Screening Ecosystem

## 3.4 Market Restraints

### 3.4.1 Regulatory Challenges in the Field of Carrier Screening

### 3.4.2 Lack of High Complexity Testing Centers

### 3.4.3 Existing Diagnostic Confidence on Conventional Screening Methods

## 3.5 Market Opportunities

### 3.5.1 Massive Scope for Adoption of Carrier Screening in Developing Nations

# 4 COMPETITIVE LANDSCAPE

## 4.1 Overview

## 4.2 Product Launches

## 4.3 Synergistic Activities

## 4.4 Acquisitions

## 4.5 Product Approvals and Fundings

## 4.6 Market Share Analysis, 2019–2020

## 4.7 Growth Share Analysis

# 5 TYPE, \$MILLION, 2020 - 2031

## 5.1 Overview

## 5.2 Expanded Carrier Screening

### 5.2.1 Customized Panel Testing

### 5.2.2 Predesigned Panel Testing

## 5.3 Targeted Carrier Screening

## **6 PRODUCT, \$MILLION, 2020 – 2031**

- 6.1 Overview
- 6.2 In Vitro Diagnostics (IVD)
- 6.3 Laboratory Developed Tests (LDT)

## **7 CARRIER SCREENING TYPE, \$MILLION, 2020-2031**

- 7.1 Overview
- 7.2 Prenatal Carrier Screening
  - 7.2.1 IVDs
  - 7.2.2 LDTs
- 7.3 Preconception Carrier Screening
  - 7.3.1 IVDs
  - 7.3.2 LDTs

## **8 TECHNOLOGY, \$MILLION, 2020 – 2031**

- 8.1 Overview
- 8.2 Next-Generation Sequencing (NGS)
- 8.3 Polymerase Chain Reaction (PCR)
  - 8.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
  - 8.3.2 Digital PCR (dPCR)
- 8.4 Microarray
- 8.5 Other Technologies

## **9 INDICATION, \$MILLION, 2020 – 2031**

- 9.1 Overview
- 9.2 Fragile X syndrome
- 9.3 Cystic Fibrosis
- 9.4 Spinal Muscular Atrophy
- 9.5 Down's Syndrome
- 9.6 Thalassemia
- 9.7 Tay-Sachs Disease
- 9.8 Huntington's Disease
- 9.9 Sickle Cell Anemia
- 9.1 Hemophilia



## 9.11 Other Indication

## **10 REGION, \$MILLION, 2020-2031**

### 10.1 Overview

### 10.2 North America

#### 10.2.1 U.S.

#### 10.2.2 Canada

### 10.3 Europe

#### 10.3.1 Germany

#### 10.3.2 France

#### 10.3.3 U.K.

#### 10.3.4 Italy

#### 10.3.5 Spain

#### 10.3.6 Netherlands

#### 10.3.7 Denmark

#### 10.3.8 Belgium

#### 10.3.9 Switzerland

#### 10.3.10 Rest-of-Europe

### 10.4 Asia-Pacific

#### 10.4.1 China

#### 10.4.2 Japan

#### 10.4.3 India

#### 10.4.4 South Korea

#### 10.4.5 Australia

#### 10.4.6 Singapore

#### 10.4.7 Rest-of-Asia-Pacific (RoAPAC)

### 10.5 Latin America

#### 10.5.1 Brazil

#### 10.5.2 Mexico

#### 10.5.3 Rest-of-Latin America (RoLA)

### 10.6 Rest-of-the-World

#### 10.6.1 Middle East

#### 10.6.2 Rest-of-Rest-of-the-World

## **11 COMPANY PROFILES**

### 11.1 Overview

### 11.2 BGI Group

- 11.2.1 Company Overview
- 11.2.2 Role of BGI Group in the Global Carrier Screening Market
- 11.2.3 SWOT Analysis
- 11.3 CENTOGENE N.V.
  - 11.3.1 Company Overview
  - 11.3.2 Role of CENTOGENE N.V. in the Global Carrier Screening Market
  - 11.3.3 Financials
  - 11.3.4 Key Insights About Financial Health of the Company
  - 11.3.5 SWOT Analysis
- 11.4 Eurofins Scientific
  - 11.4.1 Company Overview
  - 11.4.2 Role of Eurofins Scientific in the Global Carrier Screening Market
  - 11.4.3 Financials
  - 11.4.4 SWOT Analysis
- 11.5 Fulgent Genetics, Inc.
  - 11.5.1 Company Overview
  - 11.5.2 Role of Fulgent Genetics, Inc. in the Global Carrier Screening Market
  - 11.5.3 Financials
  - 11.5.4 Key Insights About Financial Health of the Company
  - 11.5.5 SWOT Analysis
- 11.6 Gene by Gene, Ltd.
  - 11.6.1 Company Overview
  - 11.6.2 Role of Gene by Gene, Ltd. in the Global Carrier Screening Market
  - 11.6.3 SWOT Analysis
- 11.7 Illumina, Inc.
  - 11.7.1 Company Overview
  - 11.7.2 Role of Illumina, Inc. in the Global Carrier Screening Market
  - 11.7.3 Financials
  - 11.7.4 Key Insights About Financial Health of the Company
  - 11.7.5 SWOT Analysis
- 11.8 Invitae Corporation
  - 11.8.1 Company Overview
  - 11.8.2 Role of Invitae Corporation in the Global Carrier Screening Market
  - 11.8.3 Financials
  - 11.8.4 Key Insights About Financial Health of the Company
  - 11.8.5 SWOT Analysis
- 11.9 Laboratory Corporation of America Holdings
  - 11.9.1 Company Overview
  - 11.9.2 Role of Laboratory Corporation of America Holdings in the Global Carrier

## Screening Market

### 11.9.3 Financials

### 11.9.2 SWOT Analysis

## 11.1 Myriad Genetics, Inc.

### 11.10.1 Company Overview

### 11.10.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market

### 11.10.3 Financials

### 11.10.4 Key Insights About Financial Health of the Company

### 11.10.5 SWOT Analysis

## 11.11 Natera, Inc.

### 11.11.1 Company Overview

### 11.11.2 Role of Natera, Inc. in the Global Carrier Screening Market

### 11.11.3 Financials

### 11.11.4 Key Insights About Financial Health of the Company

### 11.11.5 SWOT Analysis

## 11.12 OPKO Health

### 11.12.1 Company Overview

### 11.12.2 Role of OPKO Health in the Global Carrier Screening Market

### 11.12.3 Financials

### 11.12.4 Key Insights About Financial Health of the Company

### 11.12.5 SWOT Analysis

## 11.13 Quest Diagnostics Incorporated

### 11.13.1 Company Overview

### 11.13.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market

### 11.13.3 Financials

### 11.13.4 SWOT Analysis

## 11.14 Sema4

### 11.14.1 Company Overview

### 11.14.2 Role of Sema4 in the Global Carrier Screening Market

### 11.14.3 SWOT Analysis

## 11.15 Thermo Fisher Scientific Inc.

### 11.15.1 Company Overview

### 11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market

### 11.15.3 Financials

### 11.15.4 Key Insights About Financial Health of the Company

### 11.15.5 SWOT Analysis

## 11.16 Yourgene Health Plc

### 11.16.1 Company Overview

### 11.16.2 Role of Yourgene Health Plc in the Global Carrier Screening Market

11.16.3 Financials

11.16.4 Key Insights About Financial Health of the Company

11.16.5 SWOT Analysis

## List Of Figures

### LIST OF FIGURES

Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)

Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Carrier Screening Market

Figure 3: Global Carrier Screening Market (by Type), \$Million, 2020 and 2031

Figure 4: Global Carrier Screening Market (by Product), \$Million, 2020 and 2031

Figure 5: Global Carrier Screening Market (by Technology), \$Million, 2020 and 2031

Figure 6: Global Carrier Screening Market (by Indication), \$Million, 2020 and 2031

Figure 7: Global Carrier Screening Market (by Carrier Screening Type), \$Million, 2020 and 2031

Figure 8: Global Carrier Screening Market Snapshot

Figure 9: Global Carrier Screening Market: Segmentation

Figure 10: Global Carrier Screening Market: Methodology

Figure 11: Primary Research Methodology

Figure 12: Bottom-Up Approach (Segment-Wise Analysis)

Figure 13: Top-Down Approach (Segment-Wise Analysis)

Figure 14: Global Carrier Screening Market, \$Million, 2020-2031

Figure 15: Global Carrier Screening Market: COVID-19 Impact Analysis

Figure 16: Europe In Vitro Diagnostic Devices Regulation Regulatory Process

Figure 17: China NMPA Regulatory Approval Process

Figure 18: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)

Figure 19: Share of Key Developments and Strategies, January 2018-December 2021

Figure 20: Number of Product Launches (by Company), January 2018–December 2021

Figure 21: Share of Synergistic Activities (by Company), January 2018-December 2021

Figure 22: Share of Acquisitions (by Company), January 2018-November 2021

Figure 23: Share of Product Approvals and Fundings (by Company), January 2018-November 2021

Figure 24: Market Share Analysis for Global Carrier Screening Market, \$Million, 2019 and 2020

Figure 25: Growth Share Analysis for Global Carrier Screening Market (by Company), 2020

Figure 26: Global Carrier Screening Market (by Type)

Figure 27: Global Carrier Screening Market (by Type), \$Million, 2020 and 2031

Figure 28: Global Carrier Screening Market (Expanded Carrier Screening), \$Million,

2020-2031

Figure 29: Global Carrier Screening Market (Customized Panel Testing), \$Million, 2020-2031

Figure 30: Global Carrier Screening Market (Predesigned Panel Testing), \$Million, 2020-2031

Figure 31: Global Carrier Screening Market (Targeted Carrier Screening), \$Million, 2020-2031

Figure 32: Global Carrier Screening Market (by Product)

Figure 33: Global Carrier Screening Market (by Product), \$Million, 2020 and 2031

Figure 34: Global Carrier Screening Market (IVD), \$Million, 2020-2031

Figure 35: Global Carrier Screening Market (Laboratory Developed Tests (LDT)), \$Million, 2020-2031

Figure 36: Global Carrier Screening Market (by Carrier Screening type)

Figure 37: Global Carrier Screening Market (by Type), \$Million, 2020 and 2031

Figure 38: Global Carrier Screening Market (Prenatal Carrier Screening), \$Million, 2020-2031

Figure 39: Global Carrier Screening Market (Prenatal Carrier Screening (IVDs)), \$Million, 2020-2031

Figure 40: Global Carrier Screening Market (Prenatal Carrier Screening,(LDTs)), \$Million, 2020-2031

Figure 41: Global Carrier Screening Market (Preconception Carrier Screening), \$Million, 2020-2031

Figure 42: Global Carrier Screening Market (Preconception Carrier Screening (IVDs)), \$Million, 2020-2031

Figure 43: Global Carrier Screening Market (Preconception Carrier Screening (LDTs)), \$Million, 2020-2031

Figure 44: Global Carrier Screening Market (by Technology)

Figure 45: Global Carrier Screening Market (by Technology), \$Million, 2020 and 2031

Figure 46: Global Carrier Screening Market (Next-Generation Sequencing), \$Million, 2020-2031

Figure 47: Global Carrier Screening Market (Polymerase Chain Reaction), \$Million, 2020-2031

Figure 48: Global Carrier Screening Market (Polymerase Chain Reaction), \$Million, 2020 and 2031

Figure 49: Global Carrier Screening Market (RT-PCR), \$Million, 2020-2031

Figure 50: Global Carrier Screening Market (dPCR), \$Million, 2020-2031

Figure 51: Global Carrier Screening Market (Microarray), \$Million, 2020-2031

Figure 52: Global Carrier Screening Market (Other Technologies), \$Million, 2020-2031

Figure 53: Global Carrier Screening Market (by Indication)

Figure 54: Global Carrier Screening Market (by Indication), \$Million, 2020 and 2031

Figure 55: Global Carrier Screening Market (Fragile X Syndrome), \$Million, 2020-2031

Figure 56: Global Carrier Screening Market (Cystic Fibrosis), \$Million, 2020-2031

Figure 57: Global Carrier Screening Market (Spinal Muscular Atrophy), \$Million, 2020-2031

Figure 58: Global Carrier Screening Market (Down's Syndrome), \$Million, 2020-2031

Figure 59: Global Carrier Screening Market (Thalassemia), \$Million, 2020-2031

Figure 60: Global Carrier Screening Market (Tay-Sachs Disease), \$Million, 2020-2031

Figure 61: Global Carrier Screening Market (Huntington's Disease), \$Million, 2020-2031

Figure 62: Global Carrier Screening Market (Sickle Cell Anemia), \$Million, 2020-2031

Figure 63: Global Carrier Screening Market (Hemophilia), \$Million, 2020-2031

Figure 64: Global Carrier Screening Market (Other Indication), \$Million, 2020-2031

Figure 65: Global Carrier Screening (by Region): Market Snapshot

Figure 66: Global Carrier Screening Market (by Region), \$Million, 2020-2031

Figure 67: Global Carrier Screening Market (by Region), \$Million, 2020 and 2031

Figure 68: North America Carrier Screening Market, \$Million, 2020-2031

Figure 69: North America Carrier Screening Market (by Country), \$Million, 2020-2031

Figure 70: U.S. Carrier Screening Market, \$Million, 2020-2031

Figure 71: Canada Carrier Screening Market, \$Million, 2020-2031

Figure 72: Europe Carrier Screening Market, \$Million, 2020-2031

Figure 73: Europe Carrier Screening Market (by Country), \$Million, 2020-2031

Figure 74: Germany Carrier Screening Market, \$Million, 2020-2031

Figure 75: France Carrier Screening Market, \$Million, 2020-2031

Figure 76: U.K. Carrier Screening Market, \$Million, 2020-2031

Figure 77: Italy Carrier Screening Market, \$Million, 2020-2031

Figure 78: Spain Carrier Screening Market, \$Million, 2020-2031

Figure 79: Netherlands Carrier Screening Market, \$Million, 2020-2031

Figure 80: Denmark Carrier Screening Market, \$Million, 2020-2031

Figure 81: Belgium Carrier Screening Market, \$Million, 2020-2031

Figure 82: Switzerland Carrier Screening Market, \$Million, 2020-2031

Figure 83: Rest-of-Europe Carrier Screening Market, \$Million, 2020-2031

Figure 84: Asia-Pacific Carrier Screening Market, \$Million, 2020-2031

Figure 85: APAC Carrier Screening Market (by Country), \$Million, 2020-2031

Figure 86: China Carrier Screening Market, \$Million, 2020-2031

Figure 87: Japan Carrier Screening Market, \$Million, 2020-2031

Figure 88: India Carrier Screening Market, \$Million, 2020-2031

Figure 89: South Korea Carrier Screening Market, \$Million, 2020-2031

Figure 90: Australia Carrier Screening Market, \$Million, 2020-2031



- Figure 91: Singapore Carrier Screening Market, \$Million, 2020-2031
- Figure 92: RoAPAC Carrier Screening Market, \$Million, 2020-2031
- Figure 93: Latin America Carrier Screening Market, \$Million, 2020-2031
- Figure 94: Latin America Carrier Screening Market (by Country), \$Million, 2020-2031
- Figure 95: Brazil Carrier Screening Market, \$Million, 2020-2031
- Figure 96: Mexico Carrier Screening Market, \$Million, 2020-2031
- Figure 97: RoLA Carrier Screening Market, \$Million, 2020-2031
- Figure 98: RoW Carrier Screening Market, \$Million, 2020-2031
- Figure 99: Middle East Carrier Screening Market, \$Million, 2020-2031
- Figure 100: Rest-of-Rest-of-the-World Carrier Screening Market, \$Million, 2020-2031
- Figure 101: Total Number of Companies Profiled
- Figure 102: BGI Group: Product Portfolio
- Figure 103: BGI Group: SWOT Analysis
- Figure 104: CENTOGENE N.V.: Portfolio
- Figure 105: CENTOGENE N.V.: Overall Financials, 2018-2020
- Figure 106: CENTOGENE N.V.: Revenue (by Business Segment), 2018–2020
- Figure 107: CENTOGENE N.V.: Revenue (by Region), 2018-2020
- Figure 108: CENTOGENE N.V.: R&D Expenditure, 2018-2020
- Figure 109: CENTOGENE N.V.: SWOT Analysis
- Figure 110: Eurofins Scientific: Portfolio
- Figure 111: Eurofins Scientific: Overall Financials, 2018-2020
- Figure 112: Eurofins Scientific: Revenue (by Region), 2018-2020
- Figure 113: Eurofins Scientific: SWOT Analysis
- Figure 114: Fulgent Genetics, Inc.: Portfolio
- Figure 115: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
- Figure 116: Fulgent Genetics, Inc.: Revenue (by Region), 2018-2020
- Figure 117: Fulgent Genetics, Inc.: R&D Expenditure, 2018-2020
- Figure 118: Fulgent Genetics, Inc.: SWOT Analysis
- Figure 119: Gene by Gene, Ltd.: Portfolio
- Figure 120: Gene by Gene, Ltd.: SWOT Analysis
- Figure 121: Illumina, Inc.: Product Portfolio
- Figure 122: Illumina, Inc.: Overall Financials, 2018-2020
- Figure 123: Illumina, Inc.: Revenue (by Business Segment), 2018–2020
- Figure 124: Illumina, Inc.: Revenue (by Region), 2018–2020
- Figure 125: Illumina, Inc.: R&D Expenditure, 2018-2020
- Figure 126: Illumina, Inc.: SWOT Analysis
- Figure 127: Invitae Corporation: Portfolio
- Figure 128: Invitae Corporation: Overall Financials, 2018-2020
- Figure 129: Invitae Corporation: Revenue (by Business Segment), 2018–2020



- Figure 130: Invitae Corporation: Revenue (by Region), 2018-2020
- Figure 131: Invitae Corporation: R&D Expenditure, 2018-2020
- Figure 132: Invitae Corporation: SWOT Analysis
- Figure 133: Laboratory Corporation of America Holdings: Portfolio
- Figure 134: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
- Figure 135: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
- Figure 136: Laboratory Corporation of America Holdings: Revenue (by Region), 2018-2020
- Figure 137: Laboratory Corporation of America Holdings: SWOT Analysis
- Figure 138: Myriad Genetics, Inc.: Portfolio
- Figure 139: Myriad Genetics, Inc.: Overall Financials, 2018-2020
- Figure 140: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018–2020
- Figure 141: Myriad Genetics, Inc.: Revenue (by Region), 2018-2020
- Figure 142: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
- Figure 143: Myriad Genetics, Inc.: SWOT Analysis
- Figure 144: Natera, Inc.: Portfolio
- Figure 145: Natera, Inc.: Overall Financials, 2018-2020
- Figure 146: Natera, Inc.: Revenue (by Business Segment), 2018–2020
- Figure 147: Natera, Inc.: Revenue (by Region), 2018-2020
- Figure 148: Natera, Inc.: R&D Expenditure, 2018-2020
- Figure 149: Natera, Inc.: SWOT Analysis
- Figure 150: OPKO Health: Portfolio
- Figure 151: OPKO Health: Overall Financials, 2018-2020
- Figure 152: OPKO Health: Revenue (by Business Segment), 2018–2020
- Figure 153: OPKO Health: Revenue (by Region), 2018-2020
- Figure 154: OPKO Health: R&D Expenditure, 2018-2020
- Figure 155: OPKO Health: SWOT Analysis
- Figure 156: Quest Diagnostics Incorporated: Portfolio
- Figure 157: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
- Figure 158: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
- Figure 159: Quest Diagnostics Incorporated: SWOT Analysis
- Figure 160: Sema4: Portfolio
- Figure 161: Sema4: SWOT Analysis
- Figure 162: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 163: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
- Figure 164: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018–2020
- Figure 165: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018–2020
- Figure 166: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020

Figure 167: Thermo Fisher Scientific Inc.: SWOT Analysis

Figure 168: Yourgene Health Plc: Portfolio

Figure 169: Yourgene Health plc: Overall Financials, 2018-2020

Figure 170: Yourgene Health Plc: Revenue (by Business Segment), 2019–2020

Figure 171: Yourgene Health Plc: Revenue (by Region), 2018–2020

Figure 172: Yourgene Health Plc: R&D Expenditure, 2018-2020

Figure 173: Yourgene Health Plc: SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 1: Classification of Medical Device
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Companies Providing Expanded Carrier Screening
Table 6: Companies Providing Customized Panel Testing
Table 7: Companies Offering Predesigned Panel Testing
Table 8: Companies Offering Fragile X Syndrome Tests
Table 9: Companies Offering Cystic Fibrosis Tests
Table 10: Companies Offering Thalassemia Tests
Table 11: Companies Offering Huntington's Disease Tests
Table 12: Companies Offering Sickle Cell Anemia Test
Table 13: Companies Offering Hemophilia Test
Table 14: North America: Market Dynamics
Table 15: Europe: Market Dynamics
Table 16: APAC: Market Dynamics
Table 17: Latin America: Market Dynamics

## I would like to order

Product name: Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening Type, Technology, Indication, and Region - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/C5B46015AA29EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5B46015AA29EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970